Loading
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Previous close
$1.92
+$0.11 · +6.08%
Pre-market
$1.8904
−$0.0296 · -1.54%
Oct 8, 7:48 AM ET
Regular session · ET · Market data may be delayed.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Day range
Current $1.92
52-week range
Current $1.92
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
56
Mixed
Risk
65
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Day range
Current $1.92
52-week range
Current $1.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 21.05M USD | 100.56M USD | 97.06M USD | 133.62M USD | 207.09M USD |
| Cost of goods sold | 9.66M USD | 185.94M USD | 8.85M USD | — | 189.41M USD |
| Gross profit | 11.38M USD | −85.38M USD | 88.21M USD | 133.62M USD | 17.68M USD |
| Research and development | 123.07M USD | 209.24M USD | 192.12M USD | 210.42M USD | 189.41M USD |
| Selling, general, and administrative | 53.99M USD | 57.41M USD | 56.69M USD | 61.03M USD | 55.04M USD |
| Operating expenses | 157.19M USD | 59.62M USD | 239.95M USD | 271.45M USD | 55.04M USD |
| Depreciation and amortization | 9.66M USD | 8.84M USD | 8.85M USD | 8.47M USD | 8.32M USD |
| Operating income | −145.81M USD | −145M USD | −151.74M USD | −137.83M USD | −37.36M USD |
| Net income | −142.93M USD | −119.05M USD | −130.39M USD | −133.31M USD | −36.33M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.25
17.19% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.41M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM4.67M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF2.42M0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO1.5M0.01%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1.27M0.01%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA899.22K0.00%22.01B USD0.03%$32.61-1.47%
Lazard Emerging Markets Opportunities ETFEMKT822.75K0.45%184.2M USD0.74%$31.5798-1.20%
iShares Micro-Cap ETFIWC529.1K0.04%1.33B USD0.60%$183.36-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHALazard Emerging Markets Opportunities ETFEMKTiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
